PFE - Europe Approves Pfizer/BioNTech's Adapted COVID-19 Vaccine For Upcoming Autumn Vaccination Campaigns | Benzinga
The European Commission has approved Comirnaty XBB.1.5-adapted COVID-19 vaccine, developed by BioNTech SE (NASDAQ: BNTX)-Pfizer Inc (NYSE: PFE).
It is the third adaptation of this vaccine to respond to new COVID-19 variants.
The vaccine is authorized for adults, children, and infants above six months. In line with previous recommendations by EMA and the European Centre for Disease Prevention and Control ...